Enliven Therapeutics (ELVN) Operating Income Growth (1y) (2020 - 2026)
Enliven Therapeutics (ELVN) Operating Income Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,320.50 Bn | 66,320.21 Bn | - | -24.89% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.93 Bn | 468.14 Bn | 1.35 Bn | 2,150.96% |
| 5 | Vertex Pharmaceuticals | 122.22 Bn | 114.98 Bn | 2.59 Bn | 80.62% |
| 6 | Regeneron Pharmaceuticals | 69.96 Bn | 61.21 Bn | 3.31 Bn | 8.65% |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 56.07 Bn | 50.89 Bn | 1.41 Bn | 145.20% |
| 9 | Alnylam Pharmaceuticals | 37.60 Bn | 34.59 Bn | 959.66 Mn | 1,386.07% |
| 10 | Enliven Therapeutics | 3.39 Bn | 2.94 Bn | - | 12.21% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.21% |
| Dec 31, 2025 | -27.47% |
| Sep 30, 2025 | 7.29% |
| Jun 30, 2025 | -16.18% |
| Mar 31, 2025 | -21.96% |
| Dec 31, 2024 | -18.33% |
| Sep 30, 2024 | -11.63% |
| Jun 30, 2024 | -22.20% |
| Mar 31, 2024 | -58.28% |
| Dec 31, 2023 | -123.64% |
| Sep 30, 2023 | -121.77% |
| Jun 30, 2023 | -123.31% |
| Mar 31, 2023 | -89.19% |
| Dec 31, 2022 | 29.10% |
| Sep 30, 2022 | 19.95% |
| Jun 30, 2022 | 31.54% |
| Mar 31, 2022 | 15.58% |
| Dec 31, 2021 | -24.10% |
| Sep 30, 2021 | -9.32% |
| Jun 30, 2021 | -27.83% |